New Data Presented At Digestive Disease Conference May Change Prognosis For Many Patients - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
New Data Presented At Digestive Disease Conference May Change Prognosis For Many Patients


New Data Presented At Digestive Disease Conference May Change Prognosis For Many Patients

PR Newswire

CHICAGO, May 6, 2014 /PRNewswire/ -- Research presented this week at Digestive Disease Week® (DDW) provides insight into the development and new treatments of diseases, such as nonalcoholic fatty liver disease, colorectal cancer and ulcers. Key studies presented include:

For more information on these and other studies, visit www.ddw.org/press.

Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 3-6, 2014, at McCormick Place, Chicago. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.

Follow us on Twitter @DDWMeeting (www.twitter.com/DDWMeeting); hashtag #DDW14. Become a fan of DDW on Facebook (www.facebook.com/DDWMeeting).

SOURCE Digestive Disease Week

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here